Advanced search
Publication Cover
Hospital Practice Volume 48, 2020 - Issue 2
Submit an article Journal homepage
93
Views
3
CrossRef citations to date
0
Altmetric
Clinical Focus: Diabetes, Endocrine & Metabolic Disorders - Original Research

Link between body weight changes and metabolic parameters in drugs naïve subjects with type 2 diabetes treated with canagliflozin monotherapy

Eiji Kutoha Division of Clinical Research, Biomedical Center, Tokyo, Japan;b Division of Endocrinology and Metabolism, Department of Internal Medicine, Gyoda General Hospital, Saitama, Japan;c Division of Diabetes and Metabolism, Department of Internal Medicine, Higashitotsuka Memorial Hospital, Yokohama, JapanCorrespondence[email protected]
,
Asuka Wadab Division of Endocrinology and Metabolism, Department of Internal Medicine, Gyoda General Hospital, Saitama, Japan
,
Alexandra N. Kutoa Division of Clinical Research, Biomedical Center, Tokyo, Japan
,
Jyunka Hayashib Division of Endocrinology and Metabolism, Department of Internal Medicine, Gyoda General Hospital, Saitama, Japan
&
Rumi Kuriharab Division of Endocrinology and Metabolism, Department of Internal Medicine, Gyoda General Hospital, Saitama, Japan
Pages 68-74 | Received 14 Jan 2020, Accepted 17 Feb 2020, Published online: 03 Mar 2020

References

  • Whalen K, Miller S, Onge ES. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Clin Ther. 2015;37(6):1150–1166.
  • Kuriyama C, Ueta K, Arakawa K. Pharmacological and clinical profile of a novel SGLT2 inhibitor canagliflozin hydrate (CANAGLU®). Nihon Yakurigaku Zasshi. 2015;146(6):332–341.
  • Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015;1358:28–43.
  • Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes Metab. 2014;40(6 Suppl 1):S4–S11.
  • Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8(5):330–339.
  • Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME investigators. empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
  • Neal B, Perkovic V, Mahaffey KW, et al. CANVAS program collaborative group. canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
  • Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 investigators. dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
  • Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
  • Singh H, Venkatesan V. Treatment of ‘diabesity’: beyond pharmacotherapy. Curr Drug Targets. 2018;19(14):1672–1682.
  • Wright JJ, Tylee TS. Pharmacologic therapy of type 2 diabetes. Med Clin North Am. 2016;100(4):647–663.
  • Kutoh E. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone. Postgrad Med. 2011;123(1):45–52.
  • Kutoh E, Hirate M, Wada A. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin. Int J Clin Pract. 2015;69(11):1296–1302.
  • Kutoh E, Murayama T, Wada A, et al. Distinct glucose-lowering mechanisms of ipragliflozin depending on body weight changes. Drugs R D. 2016;16(4):369–376.
  • Kutoh E, Wada A, Murayama T, et al. Two glucose-lowering mechanisms of canagliflozin depending on body weight changes in drug-naïve subjects with type 2 diabetes. Drugs R D. 2018;18(4):309–315.
  • Kutoh E, Wada A, Hayashi J. Regulation of free fatty acid by sitagliptin monotherapy in drug-naïve subjects with type 2 diabetes. Endocr Pract. 2018;24(12):1063–1072.
  • Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512–517.
  • Al Jobori H, Daniele G, Adams J, et al. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab. 2017;19(6):809–813.
  • Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66–74.
  • Silvestre MP, Goode JP, Vlaskovsky P, et al. The role of glucagon in weight loss-mediated metabolic improvement: a systematic review and meta-analysis. Obes Rev. 2018;19(2):233–253.
  • Scott RV, Bloom SR. Problem or solution: the strange story of glucagon. Peptides. 2018;100:36–41.
  • Giacca A, Xiao C, Oprescu AI, et al. Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies. Am J Physiol Endocrinol Metab. 2011;300(2):E255–262.
  • Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes. 1995;44(8):863–870.
  • Hirano T. Pathophysiology of diabetic dyslipidemia. J Atheroscler Thromb. 2018;25(9):771–782.
  • Garg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019;62(4):349–357.
  • O’Keefe JH, Nassif ME, Magwire ML, et al. The elephant in the room: why cardiologists should stop ignoring type 2 diabetes. Prog Cardiovasc Dis. 2019;62(4):364–369.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.